INFLUENCE OF PARTIALLY AND FULLY PREGELATINIZED STARCH ON THE PHYSICAL AND SUSTAINED-RELEASE PROPERTIES OF HPMC-BASED KETOPROFEN ORAL MATRICES

WALEED ELBALLA; MOHAMMED SALIH

doi:10.22159/ijpps.2022v14i8.45031

Authors

WALEED ELBALLA Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan
MOHAMMED SALIH Department of Pharmaceutics, Faculty of Pharmacy, Sudan University of Science and Technology, Khartoum, Sudan, Operation Department, Amipharma Laboratories Ltd, Khartoum, Sudan https://orcid.org/0000-0002-5423-5492

DOI:

https://doi.org/10.22159/ijpps.2022v14i8.45031

Keywords:

Fully pregelatinized starch, Partially pregelatinized starch, Drug release, HPMC matrices, Sustain release

Abstract

Objective: This study aims to investigate the effect of two types of pregelatinized starch on the physical performance of HPMC matrices containing Ketoprofen as a model drug.

Methods: The design of the experiment was inspired by the monothetic analysis, in which testing factors or causes is done one factor or cause at a time, to achieve system improvements. Tablets were prepared by direct compression. The impact of the type of modified starch on the tablet's physicochemical properties was studied by testing for weight variation, friability, hardness, and drug release properties. PCP dissolution software was used to investigate the kinetics of drug release from matrix tablet formulation.

Results: The impact of the type of modified starch on tablet physicochemical attributes revealed that the weight variation of tablets was affected by the amount of modified starch used and that the combination of 64.7% partially pregelatinized starch (Starch^Ò 1500) with 9.5% HPMC (F8) was found to be the better in terms of weight variation (%RSD= 1.73%) when compared with those containing fully pregelatinized starch (LYCATAB^Ò). All formulation runs have friability that complies with pharmacopeial limits of less than 1% loss upon test conduction except for (F1). Formulations containing LYCATAB^Ò showed better friability than those containing Starch^Ò 1500, and similar results were observed in tablet hardness as well, in which the formulation containing the highest LYCATAB^Òconcentration showed a significant increase in mechanical strength (P = 0.0004) than those containing the highest concentration of Starch^Ò 1500. Finally, all formulations containing LYCATAB^Òexhibited sustained-release behavior, less than 60% of the drug was released from matrices over 14 h, and it is believed that the drug is transported via Fickian diffusion and followed either Higuchi or Peppas model (n>0.5), while all formulations containing Starch^Ò 1500 released ~90% of the drug around 2 h, this might probably be due to the high disintegration effect of the partially pregelatinized starch, which is lost upon full pregelatinization.

Conclusion: Tablet weight variation, hardness, friability, and T_50% were found to be influenced by both the type and concentration of modified starch used. While drug release characteristics were greatly affected by the type of modified starch used. For sustain-release formulations, only fully pregelatinized starch is thought to be suitable.

Downloads

Download data is not yet available.

References

Das NG, Das SK. Controlled release of oral dosage forms. Pharm Technol. 2003;15:10-7.

Ummadi S, Shravani B, Rao N, Reddy MS, Sanjeev B. Overview on the controlled release dosage form. System. 2013;7(8):51-60.

Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts. 2012;2(4):175-87. doi: 10.5681/bi.2012.027, PMID 23678458.

De Robertis S, Bonferoni MC, Elviri L, Sandri G, Caramella C, Bettini R. Advances in oral controlled drug delivery: the role of drug–polymer and interpolymer non-covalent interactions. Expert Opin Drug Deliv. 2015;12(3):441-53. doi: 10.1517/17425247.2015.966685, PMID 25267345.

Li CL, Martini LG, Ford JL, Roberts M. The use of hypromellose in oral drug delivery. J Pharm Pharmacol. 2005;57(5):533-46. doi: 10.1211/0022357055957, PMID 15901342.

Varma MVS, Kaushal AM, Garg A, Garg S. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. Am J Drug Deliv. 2004;2(1):43-57. doi: 10.2165/00137696-200402010-00003.

Rane M, Parmar J, Rajabi Siahboomi A. Hydrophilic matrices for extended oral release: influence of fillers on drug release from HPMC matrices. Pharma Times. 2010;42(4):41-5.

Garcia MAVT, Garcia CF, Faraco AAG. Pharmaceutical and biomedical applications of native and modified starch: a review. Starch‐Starke. 2020;72(7-8):1900270. doi: 10.1002/star.201900270.

Symecko CW, Rhodes CT. The effect of compaction force and type of pregelatinized starch on the dissolution of acetaminophen. Drug Dev Ind Pharm. 1997;23(3):229-38. doi: 10.3109/03639049709149798.

Nur AO, Elballa W, Osman ZA, Abdeen M. Influence of processing method, FIiller type, and applied compression force on pharmaceutical properties of ketoprofen oral matrices; 2015.

Sari R, Galda M, Lestari W, Rijal MAS. Ketoprofen-carboxymethyl chitosan microparticles prepared by spray drying: optimization and evaluation. Asian J Pharm Clin Res. 2015;8(1):331-3.

Al-Tahami K. Preparation, characterization, and in vitro release of ketoprofen-loaded alginate microspheres. Int J Appl Pharm. 2014;6(3):9-12.

Abdallah MH, Sammour OA, El-ghamry HA, El-nahas HM, Barakat W. Development and characterization of controlled release ketoprofen microspheres. J Appl Pharm Sci. 2012;2(3):6.

RK S, HGP P, MHF S. Assessing the characterizations of ketoprofen loaded and unloaded virgin coconut oil based creamy nanoemulsion. Asian J Pharm Clin Res. 2015;8(1):275-9.

Aliberti ALM, de Queiroz AC, Praça FSG, Eloy JO, Bentley MVLB, Medina WSG. Ketoprofen microemulsion for improved skin delivery and in vivo anti-inflammatory effect. AAPS PharmSciTech. 2017;18(7):2783-91. doi: 10.1208/s12249-017-0749-6, PMID 28374340.

Putri KSS, Surini S, Anwar E. Pragelatinized cassava starch phthalate as a film-forming excipient for transdermal film of ketoprofen. Asian J Pharm Clin Res. 2013;6(3):62-6.

Verma N, Deshwal S. Design and in vitro evaluation of transdermal patches containing ketoprofen. World J Pharm Res. 2014;3(3):3930-44.

British Pharmacopia. London: British pharmacopeia Commision. C and P. Appendices XII; 2013.

British Pharmacopia. Commission. London: British Pharmacopia. Appendices XVII GP; 2013.

British Pharmacopia. Commission. London: British Pharmacopia. Appendices XVII HP; 2013.

Mura P, Bramanti G, Fabbri L, Valleri M. Controlled-release matrix tablets of ketoprofen. Drug Development and Industrial Pharmacy. 1989;15(14-16):2695-706. doi: 10.3109/ 03639048909052555.

Thompson M, Ellison SLR, Wood R. Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC Technical Report) [IUPAC technical report]. Pure Appl Chem. 2002;74(5):835-55. doi: 10.1351/pac200274050835.

Elawni AE, Abdeen M, Elballa W, Abdelkreem A, Abdallah AA. Effect of binder type and concentration on physical and in vitro properties of diclofenac potassium 50 mg tablet. World J Pharm Res. 2016;5:1588-98.

Rowe RSP, Owen S. Handbook of pharmaceutical excipients. London; 2006.

Colorcon. Direct compression formulation using starch. 1500® with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry® II (85F Series); 2005.

Adebisi AO, Conway BR, Asare Addo K. The influence of fillers on theophylline release from clay matrices. Am J Pharmacol Sci. 2015;3(5):120-5.

Levina M, Rajabi Siahboomi AR. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci. 2004;93(11):2746-54. doi: 10.1002/jps.20181, PMID 15389670.

Rahman BM, Wahed MII, Khondkar P, Ahmed M, Islam R, Barman RK. Effect of starch 1500 as a binder and disintegrant in lamivudine tablets prepared by high shear wet granulation. Pakistan J Pharmaceutical Sciences. 2008;21(4).

Herman J, Remon JP, De Vilder JD. Modified starches as hydrophilic matrices for controlled oral delivery. I. Production and characterization of thermally modified starches. Int J Pharm. 1989;56(1):51-63. doi: 10.1016/0378-5173(89)90060-4.